文献速递慢性肾脏病遗传性与小管间质肾病

SGLT2抑制剂在常染色体显性多囊肾病中的应用:机制见解与治疗前景

Sodium-Glucose Cotransporter 2 Inhibitors in Autosomal Dominant Polycystic Kidney Disease: Mechanistic Insights and Therapeutic Promise.
PubMed 文献 · J Am Soc Nephrol · 2025-11-10

本文综述SGLT2抑制剂在常染色体显性多囊肾病(ADPKD)中的机制交叉点、临床前与早期临床数据及正在开展的大型试验。ADPKD进展由囊肿扩张、肾小管损伤及代谢血流动力学改变驱动,托伐普坦是唯一获FDA批准的改变疾病进程的药物。SGLT2i通过降低肾小球内压、代谢重编程及减轻缺氧微环境和炎症发挥肾脏保护作用,但可能因渗透性利尿和激活血管加压素引发担忧,导致ADPKD患者被 pivotal 结局试验系统排除,2025 KDIGO ADPKD指南明确不建议使用SGLT2i延缓肾功能下降。

要点

  • SGLT2i通过降低肾小球内压、代谢重编程等机制靶向ADPKD相关通路。
  • 2025 KDIGO ADPKD指南明确不建议使用SGLT2i延缓肾功能下降。
  • 正在开展的大型试验将评估SGLT2i在ADPKD中的安全性和有效性。

核心结论

  • SGLT2i在ADPKD中的治疗地位尚未确定,需待正在开展的大型试验结果。
  • 基因型、进展风险和合并症的分层对指导SGLT2i精准应用至关重要。

研究设计与样本

  • 本文为综述,检索并汇总SGLT2i与ADPKD病理生理机制交叉点的临床前和早期临床数据及正在开展的大型试验。

主要发现

  • SGLT2i通过降低肾小球内压、代谢重编程、减轻缺氧微环境和炎症靶向ADPKD相关机制。
  • 担忧SGLT2i可能引起渗透性利尿和激活血管加压素,导致ADPKD患者被 pivotal 结局试验系统排除。
  • 多数正在开展的试验富集携带PKD1或PKD2致病性变异的快速进展者,而DNAJB11、ALG8和ALG9等基因型代表性不足。

关键数值与推荐

  • 2025 KDIGO ADPKD指南明确建议不要使用SGLT2i来延缓ADPKD患者的肾功能下降。

临床怎么用

  • 目前不推荐使用SGLT2i延缓ADPKD肾功能下降,应等待正在开展的大型试验结果。
  • 未来应用需根据基因型、进展风险和合并症进行患者分层以指导精准治疗。

局限性

  • ADPKD患者被 pivotal 结局试验系统排除,缺乏硬终点证据。
  • 正在开展的试验对DNAJB11、ALG8和ALG9等基因型代表性不足。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disorder and a leading cause of kidney failure worldwide. Disease progression is driven by cyst expansion, tubular injury, and maladaptive metabolic and hemodynamic changes. Tolvaptan remains the only US Food and Drug Administration-approved disease-modifying therapy, however its tolerability and safety profile highlight the need for additional strategies. Sodium-glucose cotransporter 2 inhibitors (SGLT2is), initially developed for glycemic control, have demonstrated robust kidney-protective and cardioprotective effects across diverse patient populations, including those without diabetes. By lowering intraglomerular pressure, metabolic reprogramming, and attenuating hypoxic microenvironment and inflammation, SGLT2is target mechanisms that are relevant to ADPKD. However, concerns that SGLT2i may provoke osmotic diuresis and activate vasopressin led to systematic exclusion of patients with ADPKD from pivotal outcome trials. The 2025 Kidney Disease Improving Global Outcomes ADPKD guidelines explicitly advise against the use of SGLT2i for slowing kidney function decline in ADPKD. In this review, we examine mechanistic intersections between SGLT2i and ADPKD pathophysiology, summarize available preclinical and early clinical data, and discuss ongoing large trials designed to address safety and efficacy of SGLT2i in patients with ADPKD. We also highlight the importance of genetic heterogeneity, as most ongoing trials are enriched for rapid progressors carrying PKD1 or PKD2 pathogenic variants, while other genotypes such as DNAJB11 , ALG8 , and ALG9 , often associated with greater interstitial fibrosis, are underrepresented. Substratification of patients by genotype, risk of progression, and comorbidities will be essential to guide precision application of SGLT2i. Whether SGLT2i can ultimately be positioned as an adjunctive or standalone therapy for ADPKD remains unresolved.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Bou Antoun MT, Borghol AH, Souvalian L, et al. Sodium-Glucose Cotransporter 2 Inhibitors in Autosomal Dominant Polycystic Kidney Disease: Mechanistic Insights and Therapeutic Promise. J Am Soc Nephrol. 2025. PMID: 41212622. doi:10.1681/ASN.0000000943

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。